Asebio report

Biotechnology private investment increases

The biotech sector continues gaining relevance in the Spanish economy, according to the 2015 Asebio Report, recently published. Among the criteria that show this increasing trend, it is worth noting the private R&D investment, that has returned to growth with 3,75% (533.8 million Euros in 2014) after two consecutive years of downturn. This tendency contrasts to the needs of this sector, that requires an increase of the public economic aids for R&D in order to recuperate, at least, the previous levels to 2008.

“The figures of the report confirm that the biotech sector is a cornerstone in the Spanish economy. The growth in the R&D private investment points out that the companies have made a great effort to continue developing and innovating despite the numerous problems. These figures are endorsed internationally by the latest Ernst&Young Report – Beyond Borders- that shows how the global biotech sector reached a record figure of funding until 62,000 million Euros in 2015”, Bionaturis CEO, Victor Infante, has stated.

The invoicing volume is also very relevant considering that it has already reached 10.35% of the Spanish GDP, rubbing shoulders for the first time in the top ranking with other sectors such as Tourism. This indicator has not stopped growing up even during the crisis, period in which, precisely, it has registered a rise of more than 7%. In 2014 the sector overtook the record of 100,000 million Euros of invoicing and created 178,000 jobs (+3%).

The number of biotech companies (high-technology companies completely devoted to the sector, as Bionaturis Group) grew 13.36% in 2014. As in previous reports, the majority of these companies consider that the internationalization is very important for their growth, because of that, the 86% of the companies integrated […]

August 8th, 2016|Blog english|Comments Off|

Lines of our CEO, Víctor Infante, about Asebio 2012 annual report

Earlier this month of July was presented the annually ASEBIO report, published by the Spanish Biotechnology Companies Association, taken as a reference of the health of the sector in Spain. As conclusions, the press and specialized opinion highlighted the positive increase of the impact of biotechnology in Spanish GDP (7.15%), with an important rise since 2008 (2.98%), along with a growth of 23.7% of employment up to the 202,250 workers and a 26.5% increase in the turnover.

CEO: Without a doubt the big picture is encouraging and especially taking into account the economical context during this growth. This data should serve to ratify that the biotechnology sector is, and must be more and more, one of the driver vectors of growth in any developed country. However a deeper analysis reveals that we are still quite far from the impact that has on other reference countries. To get closer to expected by our country figures, no doubt that we need more “Grifols” and facilitate in everything, and not otherwise, to companies as Grifols can continue growing and acting as a big leader. Spanish biotechnology needs size, muscles, and big leaders that can complete the whole value chain. Each advanced country in our environment has at least one or two reference leading global companies especially in red biotechnology. Spain should launch a strategic plan to have within a reasonable timeframe at least one company among the top 15 in world sales. We have enough raw material, but we should take it as a matter of State and put in place mechanisms and appropriate measures to implement it.


However, it has also pointed out the decline in R&D investment, the first in ten years.

CEO: Well, it´s not a surprising […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.